132 related articles for article (PubMed ID: 12871546)
1. Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high-expressing human factor IX plasmid.
Ye X; Loeb KR; Stafford DW; Thompson AR; Miao CH
J Thromb Haemost; 2003 Jan; 1(1):103-11. PubMed ID: 12871546
[TBL] [Abstract][Full Text] [Related]
2. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo.
Miao CH; Thompson AR; Loeb K; Ye X
Mol Ther; 2001 Jun; 3(6):947-57. PubMed ID: 11407909
[TBL] [Abstract][Full Text] [Related]
3. [Human coagulation factor IX gene therapy in murine hemophilia B by hydrodynamic delivery and site-specific genomic integration].
Zhang L; Gu DS; DU WT; Liu PX; Lu SH; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2010 May; 31(5):294-9. PubMed ID: 21122306
[TBL] [Abstract][Full Text] [Related]
4. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
Cohn EF; Zhuo J; Kelly ME; Chao HJ
J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
[TBL] [Abstract][Full Text] [Related]
5. Long-term phenotypic correction in factor IX knockout mice by using ΦC31 integrase-mediated gene therapy.
Keravala A; Chavez CL; Hu G; Woodard LE; Monahan PE; Calos MP
Gene Ther; 2011 Aug; 18(8):842-8. PubMed ID: 21412285
[TBL] [Abstract][Full Text] [Related]
6. [Preparation of rAAV2/hFIX and experimentally application to gene therapy for hemophilia B].
Peng JQ; Dong XY; Peng M; Chen L; Tan SP; Yuan H; Chen FP; Xue JL; Wu XB
Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):513-8. PubMed ID: 15569526
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for hemophilia B with liver-specific element mediated by Rep-RBE site-specific integration system.
Xu Z; Ye J; Zhang A; Xie L; Shen Q; Xue J; Chen J
J Cardiovasc Pharmacol; 2015 Feb; 65(2):153-9. PubMed ID: 25295466
[TBL] [Abstract][Full Text] [Related]
8. Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.
Levin D; Lagassé HA; Burch E; Strome S; Tan S; Jiang H; Sauna ZE; Golding B
J Thromb Haemost; 2017 Apr; 15(4):721-734. PubMed ID: 28166609
[TBL] [Abstract][Full Text] [Related]
9. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients.
Qiu X; Lu D; Zhou J; Wang J; Yang J; Meng P; Hsueh JL
Chin Med J (Engl); 1996 Nov; 109(11):832-9. PubMed ID: 9275366
[TBL] [Abstract][Full Text] [Related]
10. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.
Kay MA; Rothenberg S; Landen CN; Bellinger DA; Leland F; Toman C; Finegold M; Thompson AR; Read MS; Brinkhous KM
Science; 1993 Oct; 262(5130):117-9. PubMed ID: 8211118
[TBL] [Abstract][Full Text] [Related]
11. Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice.
Wen J; Xu N; Li A; Bourgeois J; Ofosu FA; Hortelano G
J Gene Med; 2007 Nov; 9(11):1002-10. PubMed ID: 17868187
[TBL] [Abstract][Full Text] [Related]
12. Creation of a mouse expressing defective human factor IX.
Jin DY; Zhang TP; Gui T; Stafford DW; Monahan PE
Blood; 2004 Sep; 104(6):1733-9. PubMed ID: 15178576
[TBL] [Abstract][Full Text] [Related]
13. Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.
Le Quellec S; Dane A; Enjolras N; McIntosh J; Rosales C; Negrier C; Nathwani A
Haemophilia; 2019 Jan; 25(1):e11-e18. PubMed ID: 30520547
[TBL] [Abstract][Full Text] [Related]
14. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
Schneider H; Mühle C; Douar AM; Waddington S; Jiang QJ; von der Mark K; Coutelle C; Rascher W
J Gene Med; 2002; 4(1):46-53. PubMed ID: 11828387
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.
Le Quellec S; Dane AP; Barbon E; Bordet JC; Mingozzi F; Dargaud Y; Marais T; Biferi MG; Négrier C; Nathawani AC; Enjolras N
Thromb Haemost; 2019 Dec; 119(12):1956-1967. PubMed ID: 31659733
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX.
Lu W; Zhou Q; Yang H; Wang H; Gu Y; Shen Q; Xue J; Dong X; Chen J
Front Med; 2016 Jun; 10(2):212-8. PubMed ID: 27052253
[TBL] [Abstract][Full Text] [Related]
17. A new potent hFIX plasmid for hemophilia B gene therapy.
Lee JS; Lee M; Kim SW
Pharm Res; 2004 Jul; 21(7):1229-32. PubMed ID: 15290864
[TBL] [Abstract][Full Text] [Related]
18. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro.
Miao CH; Ohashi K; Patijn GA; Meuse L; Ye X; Thompson AR; Kay MA
Mol Ther; 2000 Jun; 1(6):522-32. PubMed ID: 10933977
[TBL] [Abstract][Full Text] [Related]
19. Balloon catheter delivery of helper-dependent adenoviral vector results in sustained, therapeutic hFIX expression in rhesus macaques.
Brunetti-Pierri N; Liou A; Patel P; Palmer D; Grove N; Finegold M; Piccolo P; Donnachie E; Rice K; Beaudet A; Mullins C; Ng P
Mol Ther; 2012 Oct; 20(10):1863-70. PubMed ID: 22828499
[TBL] [Abstract][Full Text] [Related]
20. Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
Brown HC; Doering CB; Herzog RW; Ling C; Markusic DM; Spencer HT; Srivastava A; Srivastava A
Hum Gene Ther; 2020 Oct; 31(19-20):1114-1123. PubMed ID: 32657150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
